You searched for "screening"

562 results found

Neuroendocrine bladder tumour

A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

How the COVID pandemic has shaped ongoing service delivery at ERIC, The Children’s Bowel & Bladder Charity

- CHARITY FOCUS - Like many organisations and charities, COVID-19 generated a rapid period of adaptation and diversification for ERIC, The Children’s Bowel and Bladder Charity. Their Head of Communications, Alina Lynden, explains what this meant for the organisation and...

Intelligent triage: improving outpatient efficiency

Background Improving outpatient (OP) efficiency and service structure is of paramount importance as the NHS seeks to manage ever increasing demand in the wake of the COVID-19 pandemic. As we re-establish services and attempt to clear the backlog, new ways...

Pyonephrosis: is the kidney always doomed?

Pyonephrosis (Greek pyon ‘pus’ + nephros ‘kidney’) is defined in Campbell-Walsh Urology [1] as an infected hydro-nephrosis associated with suppurative destruction of the renal parenchyma which results in total or near total loss of renal function. The true incidence of...

Bladder cancer diagnosis and follow up: A new proven urinary biomarker to support the post COVID-19 recovery phase

Since lockdown began most urologists have been following the advice of BAUS Oncology, to minimise the risk of exposure of patients and staff to potential COVID-19 infection: the result is an increasing backlog of patients requiring tests to determine if...

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...

Prostate cancer

Case 1 A 65-year-old man is referred to your two-week wait (2WW) clinic with a PSA of 7.0ng/mL. He has no lower urinary tract symptoms (LUTS), no past medical history, no family history of prostate cancer (PCa) and his performance...

Dietary citrate substitution in urolithiasis patients

Stone formation is dependent on supersaturation of urinary salts and urinary crystal retention. Urinary promoters (protein aggregates, cell debris) and inhibitors (citrate, magnesium, urinary macromolecules such as glycosaminoglycans and proteins) are involved in the process of stone formation [1]. Hypocitraturia...

The Urology Foundation – 2019 Report

It has been another busy year for The Urology Foundation in our mission to end the suffering caused by urology disease. We’ve taken big strides in some of the most crucial areas of our work as we work to prevent, treat and cure all urology disease.

Delivering a trainee-led Urolink educational programme – my experience in Tanzania

In May 2023, I travelled to Moshi, Tanzania, where I visited Kilimanjaro Christian Medical Centre (KCMC) – a trip which was made possible through the collaborative efforts of the British Association of Urological Surgeons (BAUS) Urolink and with the support...

Urological etymology

In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). I’ve always found the derivation of names fascinating. Anatomy lessons were made so...

iMEDicare's fundraiser for Disabled Living/Bladder and Bowel UK

Team iMEDicare Execs will climb the tallest mountain in Poland (Mount Rysy in the Tatra Mountains – 8,199 feet/2,499 metres), on the 27th of August 2023.